Medtronic Receives FDA Marketing Clearance For Complete SE Biliary Stent System

Main Category: GastroIntestinal / Gastroenterology
Also Included In: Medical Devices / Diagnostics
Article Date: 19 Nov 2007 - 4:00 PDT

email to a friend   printer friendly   opinions  

Medtronic, Inc. (NYSE: MDT), announced that it has received 510(k) marketing clearance from the U.S. Food and Drug Administration for the Complete SE (self-expanding) Biliary Stent System, which is indicated for use in the palliative treatment of malignant neoplasms in the biliary tree - cancerous tumors in the bile duct that can compromise digestion by restricting the flow of digestive fluids.

U.S. commercial sales of the new biliary stent will begin immediately in a wide size range, with diameters of 4 - 10 mm and lengths of 20 - 150 mm.

Bench testing has shown the Complete SE Biliary Stent System to be extremely accurate in terms of stent placement. Accurate stent placement can decrease the likelihood that additional stents are necessary to cover the entire narrowing of the bile duct.

The safety and effectiveness of this device in the vascular system have not been established.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

http://www.medtronic.com

• Additional
• References
• Citations